Interestingly, Hong et al. (2020) have recently performed a pilot trial to treat COVID‐19 patients with celecoxib (Celebrex ®; a selective inhibitor of COX‐2) at either 0.2 g twice or once a day. The gene discussed is PTGS2; the disease is COVID-19.